IL6 and Behcet disease: In addition to down-regulating IL-6 levels in BD manic phase, lithium, and valproic acid also affect inflammatory pathways by down-regulating T-cell activation markers IL-2 and IFN-γ and reducing lipopolysaccharide-induced dopaminergic neurotoxicity by inhibiting microglial overactivation [118, 119].